Table 1

Clinical characteristics of euDKA cases

Case patient123456789
Age (years)405827283155263964
SexFemaleMaleFemaleFemaleFemaleFemaleFemaleFemaleFemale
T1/T2T1T2T1T1T1T1T1T1T2
MDI/CSIIMDIN/AMDICSIICSIICSIICSIICSIIN/A
Duration (years)172256151813266
BMI (kg/m2)26.526.524.325.933.222.022.026.132.8
Prior A1C [% (mmol/mol)]11.4 (101.1)9.8 (83.6)7.8 (61.7)8.0 (63.9)7.0 (53.0)7.2 (55.2)6.6 (48.6)7.0 (53.0)7.8 (62.0)
Canagliflozin dose (mg)300300300100300100300300150300300
Potential contributorsURISurgery 1 week priorURI, alcoholAlcoholAlcoholExercise, alcoholExerciseGINoneURISurgery 12 h prior
Insulin dose reduction just prior to euDKAYesN/AYesNoYesYesYesUnknownNoNoNoYesN/A
Presenting plasma glucose [mg/dL (mmol/L)]220 (12.2)150 (8.3)150 (8.3)96 (5.3)224 (12.4)158 (8.8)∼125 (∼6.9)203 (11.3)190 (10.6)150 (8.3)233 (12.9)169 (9.4)
pH6.97.126.897.15
Pco2 (mmHg)1026
Bicarbonate (mEq/L)61061118159913 and then 5
Anion gap (mEq/L)251735221826212416 and then 19
Ketones*Yes (serum and urine)YesYesYesYesYesYesYesYesYesYesYesYes (serum and urine)
Where treatedICUICUICUOutpt.ICUInpt.Outpt.ICUICUOutpt.Outpt.ICUICU
  • CSII, continuous subcutaneous insulin infusion; GI, gastrointestinal; Inpt., inpatient; N/A, not available; Outpt., outpatient.

  • *Urine ketones were strongly positive in all cases.